Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 23, 2018

Primary Completion Date

May 15, 2020

Study Completion Date

May 15, 2020

Conditions
PertussisPertussis Immunisation
Interventions
BIOLOGICAL

BPZE1

Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10\^7 colony forming units (CFU) or 10\^9 CFU.

OTHER

Placebo

The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).

Trial Locations (1)

37232-2573

Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03541499 - Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults | Biotech Hunter | Biotech Hunter